PROTAC-DB: an online database of PROTACs

Abstract Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic technology with potential advantages over traditional inhibition strategies. In the past few years, this technology has achieved substantial progress and two PROTACs have been advanced into phase I clinical trials. However, this technology is still maturing and the design of PROTACs remains a great challenge. In order to promote the rational design of PROTACs, we present PROTAC-DB, a web-based open-access database that integrates structural information and experimental data of PROTACs. Currently, PROTAC-DB consists of 1662 PROTACs, 202 warheads (small molecules that target the proteins of interest), 65 E3 ligands (small molecules capable of recruiting E3 ligases) and 806 linkers, as well as their chemical structures, biological activities, and physicochemical properties. Except the biological activities of warheads and E3 ligands, PROTAC-DB also provides the degradation capacities, binding affinities and cellular activities for PROTACs. PROTAC-DB can be queried with two general searching approaches: text-based (target name, compound name or ID) and structure-based. In addition, for the convenience of users, a filtering tool for the searching results based on the physicochemical properties of compounds is also offered. PROTAC-DB is freely accessible at http://cadd.zju.edu.cn/protacdb/.

[1]  N. Gray,et al.  Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6. , 2019, Angewandte Chemie.

[2]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Philip P. Chamberlain,et al.  Development of targeted protein degradation therapeutics , 2019, Nature Chemical Biology.

[4]  Michael K. Gilson,et al.  BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology , 2015, Nucleic Acids Res..

[5]  Asher Mullard.  First antibody against COVID-19 spike protein enters phase I , 2020, Nature Reviews Drug Discovery.

[6]  C. Crews,et al.  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.

[7]  Andrew R. Leach,et al.  ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..

[8]  Dennis L. Buckley,et al.  Selective Target Protein Degradation via Phthalimide Conjugation , 2015 .

[9]  Minoru Ishikawa,et al.  Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. , 2010, Journal of the American Chemical Society.

[10]  Liu Liu,et al.  A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. , 2019, Cancer cell.

[11]  Matthieu Schapira,et al.  Targeted protein degradation: expanding the toolbox , 2019, Nature Reviews Drug Discovery.

[12]  Shaomeng Wang,et al.  Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. , 2019, Journal of medicinal chemistry.

[13]  D. Lamont,et al.  Structural basis of PROTAC cooperative recognition for selective protein degradation , 2017, Nature chemical biology.

[14]  James E. Bradner,et al.  Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.

[15]  William Farnaby,et al.  BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design , 2019, Nature Chemical Biology.

[16]  Hannah J. Maple,et al.  Developing degraders: principles and perspectives on design and chemical space† †Electronic supplementary information (ESI) available: Dataset of degraders analysed in this study. See DOI: 10.1039/c9md00272c , 2019, MedChemComm.

[17]  Igor V. Tetko,et al.  Application of Associative Neural Networks for Prediction of Lipophilicity in ALOGPS 2.1 Program , 2002, J. Chem. Inf. Comput. Sci..

[18]  I. E. Smith,et al.  Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.

[19]  Asher Mullard.  Targeted degraders clear first safety hurdles , 2020, Nature Reviews Drug Discovery.

[20]  James E. Bradner,et al.  Plasticity in binding confers selectivity in ligand induced protein degradation , 2018, Nature Chemical Biology.

[21]  C. Crews,et al.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer , 2016, Proceedings of the National Academy of Sciences.

[22]  Bin Yang,et al.  Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges. , 2019, Bioorganic & medicinal chemistry letters.

[23]  Adam J Pawson,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY , 2019, Nucleic Acids Res..

[24]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[25]  Craig M. Crews,et al.  Induced protein degradation: an emerging drug discovery paradigm , 2016, Nature Reviews Drug Discovery.

[26]  M. Koegl,et al.  Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7 , 2018, Journal of medicinal chemistry.

[27]  Melanie C. Burger,et al.  ChemDoodle Web Components: HTML5 toolkit for chemical graphics, interfaces, and informatics , 2015, Journal of Cheminformatics.

[28]  Liu Liu,et al.  Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. , 2018, Journal of medicinal chemistry.